BioCryst Pharmaceuticals (BCRX) Debt/Equity Ratio: History & Chart

BioCryst Pharmaceuticals, Inc.(BCRX)

Biotechnology · Durham, NC

$8.00-0.10 (-1.30%)

Delayed quote: Oct 6, 2026, 1:45 PM EDT

About BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company currently markets two key products: Peramivir injection: An intravenous neuraminidase inhibitor, sold under the brand names RAPIVAB, RAPIACTA, and PERAMIFLU, used for the treatment of acute uncomplicated influenza. ORLADEYO: An oral serine protease inhibitor designed to manage hereditary angioedema. BioCryst's development pipeline includes several promising candidates: BCX9930: An oral factor D inhibitor in Phase II clinical trials for complement-mediated diseases. BCX9250: An oral activin receptor-like kinase-2 inhibitor undergoing Phase I clinical evaluation for fibrodysplasia ossificans progressiva. Galidesivir: An RNA dependent-RNA polymerase inhibitor, also in Phase I, aimed at treating a range of RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company engages in strategic collaborations and in-license agreements with numerous partners. These include pharmaceutical entities like Torii Pharmaceutical Co., Ltd., Seqirus UK Limited, Shionogi & Co., Ltd., Green Cross Corporation, and Mundipharma International Holdings Limited. Their alliances also extend to governmental and academic organizations such as the National Institute of Allergy and Infectious Diseases, the Biomedical Advanced Research and Development Authority, the U.S. Department of Health and Human Services, The University of Alabama at Birmingham, Albert Einstein College of Medicine of Yeshiva University, and Industrial Research, Ltd. Established in 1986, BioCryst Pharmaceuticals, Inc. is headquartered in Durham, North Carolina.

Durham, NC

435 employees

www.biocryst.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Charles K. Gayer

View full financials

BCRX Debt to Equity Ratio Metrics

DEBT TO EQUITY RATIO

-0.90

DEBT TO EQUITY RATIO AVG TTM

-1.91

DEBT TO EQUITY RATIO AVG 3Y

-1.76

DEBT TO EQUITY RATIO AVG 5Y

-1.84

DEBT TO EQUITY RATIO AVG 10Y

-0.79

DEBT TO EQUITY RATIO AVG 15Y

-0.44

DEBT TO EQUITY RATIO AVG 20Y

-0.31

CURRENT VS TTM AVG

+52.83%

CURRENT VS 3Y AVG

+48.83%

CURRENT VS 5Y AVG

+50.85%

CURRENT VS 10Y AVG

-13.58%

CURRENT VS 15Y AVG

-106.29%

CURRENT VS 20Y AVG

-192.76%

SECTOR MEDIAN · HEALTHCARE

0.11

median of 746 covered companies

CURRENT VS SECTOR MEDIAN

-920.17%

vs the sector median at left

NAME	MARKET CAP	DEBT TO EQUITY RATIO	TTM	3Y	5Y
BioCryst Pharmaceuticals, Inc. (BCRX)	$2.03B	-0.90	-1.91	-1.76	-1.84
Progyny, Inc. (PGNY)vs ›	$2.03B	0.06	0.05	0.04	0.04
UroGen Pharma Ltd. (URGN)vs ›	$2.02B	N/A	0.04	0.02	0.01
Aurinia Pharmaceuticals Inc. (AUPH)vs ›	$2.02B	0.10	0.17	0.15	0.11
Fortrea Holdings Inc. (FTRE)vs ›	$2.05B	2.13	1.43	0.96	0.78
Alvotech (ALVO)vs ›	$2.06B	N/A	N/A	N/A	N/A
Celldex Therapeutics, Inc. (CLDX)vs ›	$2.06B	0.01	0.01	0.01	0.01
Vericel Corporation (VCEL)vs ›	$2.08B	0.25	0.31	0.32	0.33
Inspire Medical Systems, Inc. (INSP)vs ›	$1.98B	0.04	0.04	0.04	0.07
SELLAS Life Sciences Group, Inc. (SLS)vs ›	$2.10B	0.01	0.06	0.10	0.08

NAME

MARKET CAP

DEBT TO EQUITY RATIO

TTM

BioCryst Pharmaceuticals, Inc. (BCRX)

$2.03B

-0.90

-1.91

-1.76

-1.84

Progyny, Inc. (PGNY)vs ›

$2.03B

0.06

0.05

0.04

UroGen Pharma Ltd. (URGN)vs ›

$2.02B

N/A

0.04

0.02

0.01

Aurinia Pharmaceuticals Inc. (AUPH)vs ›

$2.02B

0.10

0.17

0.15

0.11

Fortrea Holdings Inc. (FTRE)vs ›

$2.05B

2.13

1.43

0.96

0.78

Alvotech (ALVO)vs ›

$2.06B

N/A

Celldex Therapeutics, Inc. (CLDX)vs ›

$2.06B

0.01

Vericel Corporation (VCEL)vs ›

$2.08B

0.25

0.31

0.32

0.33

Inspire Medical Systems, Inc. (INSP)vs ›

$1.98B

0.04

0.07

SELLAS Life Sciences Group, Inc. (SLS)vs ›

$2.10B

0.01

0.06

0.10

0.08

Debt to Equity Ratio FAQ

What is the debt to equity ratio for BioCryst Pharmaceuticals, Inc. (BCRX)?

The debt to equity ratio for BCRX stock is -0.90.

Is BioCryst Pharmaceuticals, Inc.'s debt to equity ratio high or low?

The debt to equity ratio of -0.90 is 51% above its 5-year average of -1.84, near the high end of its 5-year range (-5.55–-0.72).

What is the TTM average debt to equity ratio for BioCryst Pharmaceuticals, Inc. (BCRX)?

The TTM average debt to equity ratio for BCRX stock is -1.91.

What is the 3Y average debt to equity ratio for BioCryst Pharmaceuticals, Inc. (BCRX)?

The 3Y average debt to equity ratio for BCRX stock is -1.76.

What is the 5Y average debt to equity ratio for BioCryst Pharmaceuticals, Inc. (BCRX)?

The 5Y average debt to equity ratio for BCRX stock is -1.84.

What is the 10Y average debt to equity ratio for BioCryst Pharmaceuticals, Inc. (BCRX)?

The 10Y average debt to equity ratio for BCRX stock is -0.79.

What is the 15Y average debt to equity ratio for BioCryst Pharmaceuticals, Inc. (BCRX)?

The 15Y average debt to equity ratio for BCRX stock is -0.44.

What is the 20Y average debt to equity ratio for BioCryst Pharmaceuticals, Inc. (BCRX)?

The 20Y average debt to equity ratio for BCRX stock is -0.31.

DATE	DEBT TO EQUITY RATIO
2026-06-30	-0.90
2026-03-31	-1.55
2025-12-31	-3.68
2025-09-30	-1.76
2025-06-30	-1.67
2025-03-31	-1.84
2024-12-31	-1.77
2024-09-30	-1.80
2024-06-30	-1.73
2024-03-31	-1.74
2023-12-31	-1.81
2023-09-30	-2.06
2023-06-30	-2.13
2023-03-31	-2.30
2022-12-31	-2.52
2022-09-30	-2.97
2022-06-30	-0.72
2022-03-31	-3.73
2021-12-31	-5.55
2021-09-30	-1.15
2021-06-30	-1.53
2021-03-31	-2.11
2020-12-31	-14.51
2020-09-30	2.40
2020-06-30	1.12
2020-03-31	23.37
2019-12-31	2.21
2019-09-30	-2.05
2019-06-30	-9.02
2019-03-31	3.50
2018-12-31	1.26
2018-09-30	0.85
2018-06-30	1.12
2018-03-31	0.86
2017-12-31	0.65
2017-09-30	0.54
2017-06-30	2.25
2017-03-31	1.40
2016-12-31	34.05
2016-09-30	13.39
2016-06-30	2.29
2016-03-31	1.09
2015-12-31	0.68
2015-09-30	0.47
2015-06-30	0.39
2015-03-31	0.47
2014-12-31	0.40
2014-09-30	0.36
2014-06-30	0.33
2014-03-31	-5.24
2013-12-31	-26.64
2013-09-30	8.80
2013-06-30	-3.32
2013-03-31	-10.56
2012-12-31	-66.08
2012-09-30	3.07
2012-06-30	1.92
2012-03-31	1.30
2011-12-31	2.03
2011-09-30	1.15
2011-06-30	0.76
2011-03-31	0.55
2010-12-31	0.00
2010-09-30	0.00
2010-06-30	0.00
2010-03-31	0.00
2009-12-31	0.00
2009-09-30	0.00
2009-06-30	0.00
2009-03-31	0.00
2008-12-31	0.00
2008-09-30	0.00
2008-06-30	0.00
2008-03-31	0.00
2007-12-31	0.00
2007-09-30	0.00
2007-06-30	0.00
2007-03-31	0.00
2006-12-31	0.00
2006-09-30	0.00
2006-06-30	0.00
2006-03-31	0.00
2005-12-31	0.00
2005-09-30	0.00
2005-06-30	0.00
2005-03-31	0.00
2004-12-31	0.00
2004-09-30	0.00
2004-06-30	0.00
2004-03-31	0.00
2003-12-31	0.00
2003-09-30	0.00
2003-06-30	0.00
2003-03-31	0.00
2002-12-31	0.00
2002-09-30	0.00

DATE

DEBT TO EQUITY RATIO

2026-06-30

-0.90

2026-03-31

-1.55

2025-12-31

-3.68

2025-09-30

-1.76

2025-06-30

-1.67

2025-03-31

-1.84

2024-12-31

-1.77

2024-09-30

-1.80

2024-06-30

-1.73

2024-03-31

-1.74

2023-12-31

-1.81

2023-09-30

-2.06

2023-06-30

-2.13

2023-03-31

-2.30

2022-12-31

-2.52

2022-09-30

-2.97

2022-06-30

-0.72

2022-03-31

-3.73

2021-12-31

-5.55

2021-09-30

-1.15

2021-06-30

-1.53

2021-03-31

-2.11

2020-12-31

-14.51

2020-09-30

2.40

2020-06-30

1.12

2020-03-31

23.37

2019-12-31

2.21

2019-09-30

-2.05

2019-06-30

-9.02

2019-03-31

3.50

2018-12-31

1.26

2018-09-30

0.85

2018-06-30

1.12

2018-03-31

0.86

2017-12-31

0.65

2017-09-30

0.54

2017-06-30

2.25

2017-03-31

1.40

2016-12-31

34.05

2016-09-30

13.39

2016-06-30

2.29

2016-03-31

1.09

2015-12-31

0.68

2015-09-30

0.47

2015-06-30

0.39

2015-03-31

0.47

2014-12-31

0.40

2014-09-30

0.36

2014-06-30

0.33

2014-03-31

-5.24

2013-12-31

-26.64

2013-09-30

8.80

2013-06-30

-3.32

2013-03-31

-10.56

2012-12-31

-66.08

2012-09-30

3.07

2012-06-30

1.92

2012-03-31

1.30

2011-12-31

2.03

2011-09-30

1.15

2011-06-30

0.76

2011-03-31

0.55

2010-12-31

0.00

2010-09-30

0.00

2010-06-30

0.00

2010-03-31

0.00

2009-12-31

0.00

2009-09-30

0.00

2009-06-30

0.00

2009-03-31

0.00

2008-12-31

0.00

2008-09-30

0.00

2008-06-30

0.00

2008-03-31

0.00

2007-12-31

0.00

2007-09-30

0.00

2007-06-30

0.00

2007-03-31

0.00

2006-12-31

0.00

2006-09-30

0.00

2006-06-30

0.00

2006-03-31

0.00

2005-12-31

0.00

2005-09-30

0.00

2005-06-30

0.00

2005-03-31

0.00

2004-12-31

0.00

2004-09-30

0.00

2004-06-30

0.00

2004-03-31

0.00

2003-12-31

0.00

2003-09-30

0.00

2003-06-30

0.00

2003-03-31

0.00

2002-12-31

0.00

2002-09-30

0.00

Debt to Equity Ratio: -0.90

BCRX Debt to Equity Ratio

BCRX Average Debt to Equity Ratio Chart

BCRX Current vs Average Debt to Equity Ratio Chart

BCRX Debt to Equity Ratio Metrics

BCRX Competitors' Debt to Equity Ratio

Financial Health

Debt to Equity Ratio Formula & Definition

Debt to Equity Ratio FAQ

BCRX Debt to Equity Ratio History

Related Metrics